Agile Therapeutics appoints Amy Welsh to chief commercial officer

Agile Therapeutics announced that it has reorganized and streamlined its executive leadership team to align with its business plan to promote Twirla transdermal system growth. As part of the changes, the company announced the appointment of Amy Welsh to chief commercial officer effective November 1. Additionally, James Tursi has informed the company that he will resign from the company's board of directors effective October 7. In addition to her current responsibilities leading the Twirla marketing team, Welsh, as chief commercial officer, will assume responsibility for all the company's commercial functions. Welsh joined the Company in May 2020 as VP, marketing. The company has also appointed Geoffrey Gilmore to the newly created role of chief administrative officer. In this role, Gilmore will be responsible for all the company's general and administrative functions, including corporate secretary, legal, human resources, finance, investor relations and quality assurance. The company's executive leadership team will also include Robert Conway, the company's chief corporate planning and supply chain officer, who will be responsible for the company's manufacturing and supply chain functions as well as corporate planning, and Paul Korner, the company's chief medical officer, who will be responsible for the Company's medical and research functions and will be part of the company's business development team.